

May 11, 2016



OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:[OPK](#)) today announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE®.

Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO, Dr. Laidlaw served as Relypsa's Executive Director, Medical Affairs, and Sanofi's National Director, Medical Science Liaisons, Medical Affairs.

"Doug is a key addition to the management team in OPKO's Renal Division," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "A well-conceived and executed medical education strategy is critical to Rayaldee's acceptance by U.S. healthcare professionals."

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160511005735/en/>

OPKO Health, Inc.
Investor Relations
Tara Mackay, 305-575-4100

or

Media

Rooney & Associates

Terry Rooney, 212-223-0689

trooney@rooneyco.com

or

Marion Janic, 212-223-4017

mjanic@rooneyco.com

or

Investors

LHA

Anne Marie Fields, 212-838-3777

afields@lhai.com

or

Bruce Voss, 310-691-7100

bvoss@lhai.com

Source: OPKO Health, Inc.